Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-MUG-23-01-2020-15:19:23:857-102 - samples

ABSTRACT: Paired end shallow whole genome sequencing (sWGS) data for the identification of somatic copy number alterations (SCNA) and the estimation of tumor fractions in plasma DNA of renal cell carcinoma (RCC) patients (MonRec Cohort)

PROVIDER: EGAD00001005804 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

ena-DATASET-MUG-02-12-2021-20:16:00:427-345 - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data for the identification of genomewide somatic copy number alterations (SCNA) and the estimation of tumor fractions.

| EGAD00001008397 | EGA

ena-DATASET-MUG-01-09-2020-10:55:42:997-687 - samples

Project description:Shallow whole-genome sequencing (sWGS) data for the identification of somatic copy number alterations (SCNA) and the estimation of tumor fractions in plasma DNA of metastatic colorectal cancer patients (mCRC).

| EGAD00001006384 | EGA

ena-DATASET-MUG-04-05-2020-16:04:36:243-580 - samples

Project description:Paired end (47/98) and single end (51/98) shallow whole genome sequencing (sWGS) data for the identification of somatic copy number alterations (SCNA) and the estimation of tumor fractions in plasma DNA of colorectal cancer (CRC) patients.

| EGAD00001006101 | EGA

e50a5f0d-c339-4494-9d1d-f2b7961701dd - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data (FASTQ) for the identification of genomewide somatic copy number alterations (SCNA) and the estimation of tumor fractions.

| EGAD00001010293 | EGA

ena-DATASET-MUG-25-01-2021-19:08:23:000-259 - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data for the identification of somatic copy number alterations (SCNA) and the estimation of tumor fraction and ploidy sorted malignant CD3+/Vb+ T-cells and corresponding CD19+ non-malignant B-cells

| EGAD00001006901 | EGA

ena-DATASET-MUG-25-01-2020-09:58:43:375-169 - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data of tumor tissue from RCC patients (DAIMOND cohort)

| EGAD00001005815 | EGA

ena-DATASET-MUG-25-01-2020-09:55:51:618-168 - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data of cell-free DNA from plasma and urine from RCC patients (DAIMOND cohort)

| EGAD00001005814 | EGA

ena-DATASET-MUG-23-01-2020-15:27:37:770-103 - samples

Project description:Paired end shallow whole genome sequencing (sWGS) data of cell-free DNA from plasma from self-reporting healthy individuals (MonRec Cohort)

| EGAD00001005805 | EGA

Transcriptome analysis of normal kidney, primary and metastasis ccRCC

Project description:Understanding gene expression changes during transformation from normal tissue to primary RCC and then to metastasis is important. Such analysis is pivotal for undertanding biology in renal cancer and also to unearth novel gene targets. Hence, we examined global transcriptome profile of normal renal tissue, primary RCC and metastasis RCC tumors, identifying important RCC biomarkers

2018-10-16 | GSE105261 | GEO

PGRMC1 is a novel potential tumor biomarker of human renal cell carcinoma based on quantitative proteomics and integrative biological assessments

Project description:Progesterone receptor membrane component 1 (PGRMC1) is widely observed at elevated expression levels in multiple human cancers. However, the associations of PGRMC1 with renal cancer are not clear and merit further study. In this report, we report a systematic, integrative biological assessment of PGRMC1 in renal cell carcinoma (RCC), encompassing quantitative proteomics, immunohistochemical profiling, and its clinicopathologic significance. We identified that PGRMC1 is increased to 3.91-fold in RCC tissues when compared with its autologous para-cancerous tissues by a quantitative proteomic analysis. PGRMC1 was widely increased in 63.7% RCC samples (86/135) by immunohistochemical validation. Meanwhile the average expression level of serum PGRMC1 in RCC patients (n=18) was significantly increased to 1.67-fold compared with the healthy persons. Moreover PGRMC1 upregulation is correlated with tumor malignancy level and a poor overall survival for RCC. And PGRMC1 overexpression promotes cell proliferation for renal cancer cells in vitro. Our findings demonstrate that PGRMC1 is a novel potential biomarker and therapeutic target for renal cancer due to PGRMC1 roles in promoting RCC-associated phenotypes in vitro and in vivo.

2017-01-24 | PXD004595 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data